Financial Performance - The company achieved a revenue of RMB 15.619 billion and a net profit attributable to shareholders of RMB 1.387 billion for the year 2024, with a net cash flow from operating activities of RMB 3.636 billion[17]. - The company's operating revenue for 2024 was approximately ¥15.62 billion, a decrease of 6.17% compared to ¥16.65 billion in 2023[40]. - The net profit attributable to shareholders for 2024 was approximately ¥1.39 billion, down 3.90% from ¥1.44 billion in 2023[40]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 was approximately ¥1.32 billion, a decrease of 3.99% compared to ¥1.37 billion in 2023[40]. - The net cash flow from operating activities for 2024 was approximately ¥3.64 billion, down 7.45% from ¥3.93 billion in 2023[40]. - Basic earnings per share for 2024 decreased by 2.63% to CNY 0.74 compared to CNY 0.76 in 2023[41]. - The weighted average return on equity for 2024 was 9.74%, down 1.26 percentage points from 11.00% in 2023[41]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares to all shareholders, based on the total share capital as of the dividend record date[8]. - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares (tax included) to all shareholders in 2024, reflecting its commitment to returning value to investors[59]. Research and Development - The company has launched over 20 innovative drug projects in various fields, with 9 projects advancing to clinical phase II or beyond[17]. - The company is leveraging AI technology to enhance efficiency across its operations, including drug research and development, and has deployed a leading AI model in its core business[21]. - Continued investment in research and development is planned to support innovation and competitiveness in the pharmaceutical sector[40]. - The company has established a comprehensive R&D system covering chemical preparations and biological products, focusing on respiratory and oncology immunology fields[68]. - The total R&D investment for the reporting period was 1.532 billion RMB, accounting for 9.81% of total revenue[139]. - The company is committed to advancing its research and development efforts across multiple therapeutic areas, including infectious diseases and reproductive health[141]. Product Development and Pipeline - The company’s innovative drug pipeline in the respiratory field includes over 10 innovative drugs, with significant progress in clinical trials[19]. - The company’s anti-influenza drug "Mapasavir" has shown superior efficacy in clinical trials, with the registration application accepted by the drug regulatory authority[19]. - The company has initiated the NDA application for Marpasiwe in August 2024, aiming for a swift market entry[53]. - The company is advancing multiple R&D projects in respiratory diseases, including TSLP monoclonal antibody and IL-4R monoclonal antibody[139]. - The company is developing JP-1366 injection for the treatment of bleeding due to peptic ulcers, currently in clinical application[143]. Market Strategy and Expansion - Future outlook includes strategic market expansion and potential mergers and acquisitions to drive growth[40]. - The company aims to strengthen its market position in the respiratory disease treatment sector, benefiting from policy-driven market expansion[52]. - The company is focusing on the development of new products and technologies to enhance its market position[40]. - The company is expanding its international presence by establishing subsidiaries in the Philippines and the Netherlands, successfully obtaining drug operation licenses and building quality systems[57]. - The company plans to build its first overseas factory in Jakarta, Indonesia, in 2024, to strengthen its global supply capabilities and expand into high-end markets in Europe and the United States[81]. Financial Management and Investments - The company has conducted five share buybacks since 2020, investing nearly 2.7 billion yuan, with the fifth phase buyback of approximately 500 million yuan completed by March 2025[58]. - The company reported a net cash flow from investment activities of -1.15 billion RMB, primarily due to increased purchases of large certificates of deposit[91]. - The company’s investment strategy focuses on long-term growth through capital increases and new establishment investments[159]. - The company’s investment in Joincare Pharma resulted in a loss of 0.08 million RMB for the period[159]. Compliance and Governance - The company has established a dedicated compliance management department to ensure compliance in production, circulation, and sales, enhancing its operational integrity[127]. - The company emphasizes investor communication and has designated a department to manage investor relations and information disclosure[196]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with all shareholders[197]. - The company has implemented measures to manage insider information, ensuring no insider trading occurred during the reporting period[200]. Sustainability and ESG - The company received an AA rating from MSCI for its ESG performance and was included in the S&P Global Sustainable Development Yearbook (China Edition) for 2024, highlighting its commitment to sustainable practices[61]. - The company is focused on green sustainable development, improving environmental standards, and monitoring environmental information[173].

Group 1 - Health元 (600380.SH) released its 2024 annual report on April 8, 2025, indicating that 359 institutional investors disclosed holding shares, totaling 1.156 billion shares, which accounts for 61.65% of the total share capital [1] - The top ten institutional investors hold a combined 56.94% of shares, with a decrease of 3.05 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, four funds increased their holdings, with a total increase of 0.16%, while ten funds decreased their holdings, with a total decrease of 0.31% [2] - A total of 337 new public funds were disclosed this period, including several focused on innovative drugs and healthcare [2] - One foreign fund, Abu Dhabi Investment Authority, reduced its holdings slightly compared to the previous quarter [2]

Group 1 - The company has agreed to provide joint liability guarantees for its wholly-owned and controlled subsidiaries to apply for credit financing of up to RMB 20.201 billion or equivalent foreign currency from banks such as the National Development Bank [1][2][18] - The total amount of guarantees is approximately RMB 20.201 billion, with RMB 9.13 billion for subsidiaries with a debt-to-asset ratio exceeding 70% and RMB 19.288 billion for those below 70% [2] - The total guarantees account for 56.56% of the company's most recent audited total assets of RMB 35.718 billion, pending approval at the company's shareholders' meeting [2] Group 2 - The company has a total guarantee balance of RMB 2.983 billion as of March 31, 2025, with RMB 1.576 billion for subsidiaries with a debt-to-asset ratio exceeding 70% and RMB 1.407 billion for those below 70% [18] - The guarantee balance represents 20.52% of the company's most recent audited net assets attributable to shareholders of RMB 14.534 billion [18] - As of March 31, 2025, there are no overdue guarantees from the company or its controlled subsidiaries [19] Group 3 - The company has several wholly-owned and controlled subsidiaries, including Shenzhen Haibin Pharmaceutical Co., Ltd. and Shenzhen Taotai Pharmaceutical Co., Ltd., which are involved in various pharmaceutical and healthcare-related businesses [3][4][5] - The subsidiaries have different registered capitals and main business activities, such as the production and sale of pharmaceutical products, research and development, and import-export operations [3][4][5][6] - The company is actively involved in the pharmaceutical industry, focusing on the production of various drug forms, including oral solutions, tablets, and inhalation preparations [4][5][6] Group 4 - The company held its ninth board meeting on April 7, 2025, where it reviewed and approved the proposal for credit financing and guarantees for its subsidiaries [18] - The board authorized the company's legal representative or their authorized person to sign relevant documents regarding the credit financing and guarantees [18] - The proposal will be submitted for approval at the company's shareholders' meeting [18]

Core Insights - Health元 reported a total revenue of 15.619 billion yuan and a net profit attributable to shareholders of 1.387 billion yuan for the year 2024, with a net operating cash flow of 3.636 billion yuan [1] - The company has established a strong position in the respiratory drug market, achieving a 22-fold growth in respiratory products since the launch of its first high-end inhalation formulation in 2019 [1][2] - Health元 is advancing its innovative drug pipeline in the respiratory field, with over 10 innovative drugs in development, including the flu drug "Marpacisavir," which has completed Phase III clinical trials [2][3] Revenue and Profitability - The company achieved an operating revenue of 15.619 billion yuan and a net profit of 1.387 billion yuan for 2024 [1] - The net profit after deducting non-recurring items was 1.319 billion yuan, indicating a strong financial performance [1] Product Development and Innovation - Health元 has developed over 10 first-class innovative drugs in the respiratory field, covering inhalation, oral, and injection forms [2] - The flu drug "Marpacisavir" has shown superior treatment effects, significantly shortening the duration of flu symptoms and demonstrating rapid relief for adolescents [2] - The company is also focusing on chronic obstructive pulmonary disease (COPD) with multiple first-in-class drugs, including TSLP monoclonal antibody and IL-4R monoclonal antibody, both in Phase II clinical trials [2] Strategic Collaborations - Health元 is collaborating with Bayer to develop a novel oral drug for COPD, which is a global first in its class, targeting the PREP enzyme to control inflammation [3] Embracing AI Technology - The company has begun integrating AI technology across its business operations to enhance efficiency and accelerate drug development processes [5] - Health元 has deployed advanced AI models for target identification, molecular design, and screening, significantly reducing research and development timelines [5] Future Outlook - The global pharmaceutical industry is undergoing significant transformation, with AI technology reshaping drug development paradigms [6] - Health元 aims to position itself as a leader in innovative respiratory drugs in the Chinese A-share market [3][6]

证券时报•数据宝统计显示，公司今日公布了2024年报，共实现营业收入156.19亿元，同比下降6.17%， 实现净利润13.87亿元，同比下降3.90%，基本每股收益为0.74元，加权平均净资产收益率为9.74%。 资金面上看，该股今日主力资金净流出4817.34万元，近5日主力资金净流出1.16亿元。 两融数据显示，该股最新融资余额为5.71亿元，近5日减少2854.40万元，降幅为4.76%。 按申万行业统计，健康元所属的医药生物行业共有80家公司公布了2024年度分配方案，派现金额最多的 是药明康德，派现金额为76.92亿元，其次是云南白药、恒瑞医药，派现金额分别为21.14亿元、12.75亿 元。（数据宝） 4月7日健康元发布2024年度分配预案，拟10派2元（含税），预计派现金额合计为3.66亿元。派现额占 净利润比例为26.39%，这是公司上市以来，累计第21次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派2元（含税） | 3.66 | 1.76 ...

健康元药业集团股份有限公司 二〇二四年度 审计报告 致同会计师事务所（特殊普通合伙） | | | | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-140 | 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 审计报告 致同审字（2025）第 442A007956 号 健康元药业集团股份有限公司全体股东： 一、审计意见 我们审计了健康元药业集团股份有限公司（以下简称"健康元"）财务报 表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利 润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附 注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了健康元 2 ...

健康元药业集团 2024年度独立董事述职报告 健康元药业集团股份有限公司 2024 年度独立董事述职报告 作为健康元药业集团股份有限公司（以下简称：本公司）独立董事，2024 年度，本人严格遵照《公司法》、《上市公司治理准则》、《上市公司独立董事 管理办法》等法律、法规及《公司章程》、《独立董事年报工作制度》等相关规 定，认真履行独立董事职责，出席董事会和股东大会会议，依托专业知识为公司 经营决策和规范运作提出意见和建议，并对公司相关事项发表了独立意见，切实 维护公司和全体股东的利益。 现将本人2024年度履职情况述职如下： 一、本人基本情况及独立性说明 （一） 个人基本情况 1966年生，博士研究生学历。曾任徐州医科大学药学院院长、副校长，现任 徐州医科大学教授、药理学博士生导师，本公司及江苏恩华药业股份有限公司独 立董事。现为教育部高等学校药学类专业教学指导委员会委员、江苏省理学2类 研究生教育指导委员会主任委员、江苏省药理学会副理事长、江苏省药理学会新 药临床前药理专业委员会主任委员。主持国家自然科学基金、江苏省自然科学基 金等多项项目，以通讯作者发表SCI收录论文90余篇，以第一完成人获发明专利 10 ...

健康元药业集团 2024 年度独立董事述职报告 健康元药业集团股份有限公司 2024 年度独立董事述职报告 作为健康元药业集团股份有限公司（以下简称：本公司）独立董事，2024年度， 本人严格遵照《公司法》、《上市公司独立董事管理办法》等法律、法规及《公司章 程》、《独立董事年报工作制度》等相关规定，认真履行独立董事职责，出席董事会 和股东大会会议，依托专业知识为公司经营决策和规范运作提出意见和建议，并对公 司相关事项发表了独立意见，切实维护公司和全体股东的利益。 现将本人2024年度履职情况述职如下： 一、本人基本情况及独立性说明 （一）个人基本情况 1976 年生，大学本科毕业。中华全国律师协会会员，腾讯大粤房产智库成员。2007 年起至今任广东国晖律师事务所律师、合伙人。先后担任多家企业常年法律顾问，全 面负责企业法律事务的审核、合同的起草及修订、出具法律意见书等，有丰富的处理 各种类型案件的诉讼经验，现任本公司独立董事。本人在企业法律事务、合规管理、 法律风险管控等方面具有丰富的经验。 （二）独立性情况说明 本人作为公司的独立董事，具备独立性，不属于下列任何情形 1、在公司或者其附属企业任职的人员及其 ...

健康元药业集团 2024 年度总裁工作报告 一、2024 年经营状况概述 2024 年，公司实现营业收入 156.19 亿元，归母净利润 13.87 亿元。着眼未 来，公司坚定加大研发投入力度，推动技术创新与管线升级。同时，公司经营 现金流状况保持良好态势，经营性现金流净额达 36.36 亿元，体现了公司稳健 的经营理念、良好的盈利能力、较强的抗风险能力和高效的现金流管理水平， 为公司的长远发展奠定了坚实基础。 回首过去一年，在全体员工的共同努力下，公司在多个领域取得显著成绩。 目前，公司已成功储备二十余款创新药物，广泛覆盖呼吸、镇痛、消化、心血 管及精神类疾病等重要治疗领域。其中，多款药物顺利推进至 II 期临床及以后 阶段，研发进度显著提速。同时，公司积极进行全球化拓展，与国内外知名科 研机构和药企开展合作，引进先进技术与理念，进一步增强了自身的研发实力 和创新能力。 二、2024 年经营亮点 （一）创新药管线加速突破，呼吸领域创新成果丰硕 健康元始终坚持以临床实际需求为导向，凭借高强度研发投入与差异化创 新，构建起具有竞争力的创新药管线。2024 年，健康元（不含丽珠集团）研发 1 / 5 健康元药业集 ...

健康元药业集团 2024 年度会计师事务所履职情况评估报告 健康元药业集团股份有限公司 2024 年度会计师事务所履职情况评估报告 健康元药业集团股份有限公司（以下简称：本公司）聘请致同会计师事务所 （特殊普通合伙）（以下简称：致同或致同会计师事务所）作为公司 2024 年度财 务及内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市 公司选聘会计师事务所管理办法》，公司对致同会计师事务所 2024 年度履职情况 进行评估。经评估，公司认为致同资质等方面合规有效，履职保持独立性，勤勉 尽责，公允表达意见，具体情况如下： 一、资质条件 致同会计师事务所（特殊普通合伙）成立于 1981 年，是在北京注册的中国大 型会计师事务所之一，前身是北京会计师事务所，2011 年 12 月 22 日经北京市财 政局批准转制为特殊普通合伙，2012 年更名为致同会计师事务所（特殊普通合伙）。 致同会计师事务所（特殊普通合伙）具备证券、期货相关业务从业资格，已取得 会计师事务所执业证书（证书编号:11010156）、证券、期货相关业务许可证（证 书序号：000487）。 截至 2024 年末，致同会计师事务所从业人 ...